Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 47,015 shares, a decrease of 59.2% from the October 31st total of 115,295 shares. Based on an average daily volume of 29,406 shares, the days-to-cover ratio is presently 1.6 days.

A number of analysts recently issued reports on the company. Maxim Group set a $7.00 target price on Can-Fite BioPharma and gave the stock a “buy” rating in a research note on Tuesday, October 17th. ValuEngine cut Can-Fite BioPharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 7th. Finally, HC Wainwright set a $6.00 target price on Can-Fite BioPharma and gave the stock a “buy” rating in a research note on Tuesday, October 31st.

Shares of Can-Fite BioPharma (CANF) opened at $1.44 on Friday. Can-Fite BioPharma has a 52 week low of $1.31 and a 52 week high of $2.67.

COPYRIGHT VIOLATION WARNING: “Can-Fite BioPharma Ltd. (CANF) Short Interest Update” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.watchlistnews.com/can-fite-biopharma-ltd-canf-short-interest-update/1738289.html.

Can-Fite BioPharma Company Profile

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can-Fite BioPharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.